Skip to main content Accessibility help

We use cookies to distinguish you from other users and to provide you with a better experience on our websites. Close this message to accept cookies or find out how to manage your cookie settings.

Close cookie message
×
Hostname: page-component-586b7cd67f-2brh9 Total loading time: 0 Render date: 2024-11-24T09:21:38.153Z Has data issue: false hasContentIssue false

32 - Monitoring pharmaceutical interventions with IVUS

from Monitoring pharmaceutical interventions

Published online by Cambridge University Press:  03 December 2009

By
Stephen. J Nicholls ,
Steven E. Nissen  and
E. Murat Tuzcu
Edited by
Jonathan Gillard ,
Martin Graves ,
Thomas Hatsukami  and
Chun Yuan
Stephen. J Nicholls
Affiliation:
The Cleveland Clinic Foundation, Cleveland OH, USA
Steven E. Nissen
Affiliation:
The Cleveland Clinic Foundation, Cleveland OH, USA
E. Murat Tuzcu
Affiliation:
The Cleveland Clinic Foundation, Cleveland OH, USA
Jonathan Gillard
Affiliation:
University of Cambridge
Martin Graves
Affiliation:
University of Cambridge
Thomas Hatsukami
Affiliation:
University of Washington
Chun Yuan
Affiliation:
University of Washington
Get access

Summary

Introduction

A number of therapeutic strategies have been demonstrated to have a profound impact on coronary artery disease. Accordingly, these agents have become an integral component of cardiovascular prevention regimens. In many cases, however, initiation of therapy after a clinical event is often too late, whether that is myocardial ischemia, transient ischemic attack or more focal infarction. In addition, the majority of clinical events are not prevented by the use of these therapies. As atherosclerotic cardiovascular disease remains the scourge of Western societies and is becoming increasingly prevalent within developing nations, there is an ongoing need to develop interventions that effectively reduce vascular risk.

While the final determinant of proof of efficacy of these agents resides in their ability to prevent clinical events, any assessment of an agent must be performed on the background of a combination of agents with proven efficacy. The background use of multiple efficacious agents has resulted in progressively lower event rates in patients assigned to placebo arms in clinical trials. As a result, an increasingly larger number of patients need to be followed for longer time periods in clinical trials to observe event rates that allow for an evaluation of the efficacy of these agents. As development of experimental agents is a long and costly process, it has become increasingly attractive to assess the effect of agents on a number of surrogate endpoints, in order to provide preliminary information in the design of large-scale clinical event trials.

Keywords

atherosclerotic plaquecoronary arteryintravascular ultrasoundlow density lipoproteinneointimal hyperplasia
Type
Chapter
Information
Carotid Disease
The Role of Imaging in Diagnosis and Management
 , pp. 451 - 463
Publisher: Cambridge University Press
Print publication year: 2006

Access options

Get access to the full version of this content by using one of the access options below. (Log in options will check for institutional or personal access. Content may require purchase if you do not have access.)

References

4S Investigators. (1994). Randomised trial of cholesterol lowering in 4444 patients with coronary heart disease: the Scandinavian Simvastatin Survival Study (4S). Lancet, 344, 1383–9.
Achenbach, S. and Daniel, W. G. (2004). Imaging of coronary atherosclerosis using computed tomography: current status and future directions. Current Atherosclerosis Reports, 6, 213–18.CrossRefGoogle ScholarPubMed
Ambrose, J. A., Tannenbaum, M. A., Alexopoulos, D., et al. (1988). Angiographic progression of coronary artery disease and the development of myocardial infarction. Journal of the American College of Cardiology, 12, 56–62.CrossRefGoogle ScholarPubMed
Arntz, H. R., Agrawal, R., Wunderlich, W., et al. (2000). Beneficial effects of pravastatin (+/-colestyramine/niacin) initiated immediately after a coronary event (the randomized Lipid-Coronary Artery Disease L-CAD Study). American Journal of Cardiology, 86, 1293–8.CrossRefGoogle Scholar
Badimon, J. J., Badimon, L. and Fuster, V. (1990). Regression of atherosclerotic lesions by high density lipoprotein plasma fraction in the cholesterol-fed rabbit. Journal of Clinical Investigation, 85, 1234–41.CrossRefGoogle ScholarPubMed
Badimon, J. J., Badimon, L., Galvez, A., et al. (1989). High density lipoprotein plasma fractions inhibit aortic fatty streaks in cholesterol-fed rabbits. Laboratory Investigation, 60, 455–61.Google ScholarPubMed
Berenson, G. S., Wattigney, W. A., Tracy, R. E., et al. (1992). Atherosclerosis of the aorta and coronary arteries and cardiovascular risk factors in persons aged 6 to 30 years and studied at necropsy (The Bogalusa Heart Study). American Journal of Cardiology, 70, 851–8.CrossRefGoogle Scholar
Blankenhorn, D. H., Azen, S. P., Kramsch, D. M., et al. (1993). Coronary angiographic changes with lovastatin therapy. The Monitored Atherosclerosis Regression Study (MARS). The MARS Research Group. Annals of Internal Medicine, 119, 969–76.CrossRefGoogle Scholar
Brown, B. G., Zhao, X.-Q., Chait, A., et al. (2001). Simvastatin and niacin, antioxidant vitamins, or the combination for the prevention of coronary disease. New England Journal of Medicine, 345, 1583–92.CrossRefGoogle ScholarPubMed
Cannon, C. P., Braunwald, E., McCabe, C. H., et al. (2004). Intensive versus moderate lipid lowering with statins after acute coronary syndromes. New England Journal of Medicine, 350, 1495–504.CrossRefGoogle ScholarPubMed
Chiesa, G., Monteggia, E., Marchesi, M., et al. (2002). Recombinant Apolipoprotein A-IMilano infusion into rabbit carotid artery rapidly removes lipid from fatty streaks. Circulation Research, 90, 974–80.CrossRefGoogle Scholar
Choudhury, R. P., Fuster, V., Badimon, J. J., et al. (2002). Magnetic resonance imaging and characterization of atherosclerotic plaque: emerging applications and molecular imaging. Arteriosclerosis, Thrombosis and Vascular Biology, 22, 1065–74.CrossRefGoogle ScholarPubMed
Cote, G., Tardif, J. C., Lesperance, J., et al. (1999). Effects of probucol on vascular remodeling after coronary angioplasty. Multivitamins and Protocol Study Group. Circulation, 99, 30–5.CrossRefGoogle ScholarPubMed
Downs, J. R., Clearfield, M., Weis, S., et al. (1998). Primary prevention of acute coronary events with lovastatin in men and women with average cholesterol levels: results of AFcaps/Texcaps. AirForce/Texas Coronary Atherosclerosis Prevention Study. Journal of the American Medical Association, 279, 1615–22.CrossRefGoogle Scholar
Eisen, H. J., Tuzcu, E. M., Dorent, R., et al. (2003). Everolimus for the prevention of allograft rejection and vasculopathy in cardiac-transplant recipients. New England Journal of Medicine, 349, 847–58.CrossRefGoogle ScholarPubMed
Falk, E., Shah, P. K. and Fuster, V. (1995). Coronary plaque disruption. Circulation, 92, 657–71.CrossRefGoogle ScholarPubMed
Franceschini, G., Sirtori, C. R., Capurso, A., 2nd, et al. (1980). A-IMilano apoprotein. Decreased high density lipoprotein cholesterol levels with significant lipoprotein modifications and without clinical atherosclerosis in an Italian family. Journal of Clinical Investigation, 66, 892–900.CrossRefGoogle Scholar
Fuessl, R. T., Hoepp, H. W. and Sechtem, U. (1999). Intravascular ultrasonography in the evaluation of results of coronary angioplasty and stenting. Current Opinion in Cardiology, 14, 471–9.CrossRefGoogle ScholarPubMed
Giroud, D., Li, J. M., Urban, P., et al. (1992). Relation of the site of acute myocardial infarction to the most severe coronary arterial stenosis at prior angiography. American Journal of Cardiology, 69, 729–32.CrossRefGoogle ScholarPubMed
Glagov, S., Weisenberg, E., Zarins, C. K., et al. (1987). Compensatory enlargement of human atherosclerotic coronary arteries. New England Journal of Medicine, 316, 1371–5.CrossRefGoogle ScholarPubMed
Gordon, T., Castelli, W. P., Hjortland, M. C., et al. (1977). High density lipoprotein as a protective factor against coronary heart disease. The Framingham Study. American Journal of Medicine, 62, 707–14.CrossRefGoogle ScholarPubMed
HPS Investigators. (2002) Medical research council/BHF Heart Protection Study of cholesterol lowering with simvastatin in 20,536 high-risk individuals: a randomised placebo-controlled trial. Investigators. Lancet, 360, 7–22.CrossRef
Jensen, L. O., Thayssen, P., Pedersen, K. E., et al. (2004). Regression of coronary atherosclerosis by simvastatin: a serial intravascular ultrasound study. Circulation, 110, 265–70.CrossRefGoogle ScholarPubMed
Jukema, J. W., Bruschke, A. V., Boven, A. J., et al. (1995). Effects of lipid lowering by pravastatin on progression and regression of coronary artery disease in symptomatic men with normal to moderately elevated serum cholesterol levels. The Regression Growth Evaluation Statin Study (REGRESS). Circulation, 91, 2528–40.CrossRefGoogle Scholar
Kapadia, S. R., Nissen, S. E. and Tuzcu, E. M. (1999). Impact of intravascular ultrasound in understanding transplant coronary artery disease. Current Opinion in Cardiology, 14, 140–50.CrossRefGoogle ScholarPubMed
Keck, B. M., Bennett, L. E., Rosendale, J., et al. (1999). Worldwide thoracic organ transplantation: a report from the UNOS/ISHLT International Registry for Thoracic Organ Transplantation. Clinical Transplants, 35–49.Google ScholarPubMed
Knoflach, M., Kiechl, S., Kind, M., et al. (2003). Cardiovascular risk factors and atherosclerosis in young males: ARMY study (Atherosclerosis Risk-Factors in Male Youngsters). Circulation, 108, 1064–9.CrossRefGoogle Scholar
Kobashigawa, J. A., Tobis, J. M., Starling, R. C., et al. (2005). Intravascular ultrasound validation study among heart transplant recipients. Outcomes after 5 years. Journal of the American College of Cardiology, 45, 1532–7.CrossRefGoogle Scholar
Koga, N., Iwata, Y. and Yamamoto, A. (1992). Angiographic and pathological studies on regression of coronary atherosclerosis of FH patients who received LDL-apheresis treatment. Artificial Organs, 16, 171–6.CrossRefGoogle ScholarPubMed
LaRosa, J. C., Grundy, S. M., Waters, D. D., et al. (2005). Intensive lipid lowering with atorvastatin in patients with stable coronary disease. New England Journal of Medicine, 52, 1425–35.CrossRefGoogle Scholar
Lindahl, B., Toss, H., Siegbahn, A., et al. (2000). Markers of myocardial damage and inflammation in relation to long-term mortality in unstable coronary artery disease. FRISC Study Group. Fragmin during Instability in Coronary Artery Disease. New England Journal of Medicine, 343, 1139–47.CrossRefGoogle Scholar
LIPID Study Group. (1998). Prevention of cardiovascular events and death with pravastatin in patients with coronary heart disease and a broad range of initial cholesterol levels. The Long-Term Intervention with Pravastatin in Ischaemic Disease (LIPID) Study Group. New England Journal of Medicine, 339, 1349–57.
Little, W. C., Constantinescu, M., Applegate, R. J., et al. (1988). Can coronary angiography predict the site of a subsequent myocardial infarction in patients with mild-to-moderate coronary artery disease?Circulation, 78, 1157–66.CrossRefGoogle ScholarPubMed
Losordo, D. W., Rosenfield, K., Kaufman, J., et al. (1994). Focal compensatory enlargement of human arteries in response to progressive atherosclerosis. In vivo documentation using intravascular ultrasound. Circulation, 89, 2570–7.CrossRefGoogle ScholarPubMed
Lutgens, E., Suylen, R. J., Faber, B. C., et al. (2003). Atherosclerotic plaque rupture: local or systemic process?Arteriosclerosis, Thrombosis and Vascular Biology, 23, 2123–30.CrossRefGoogle ScholarPubMed
MAAS Effect of simvastatin on coronary atheroma: the Multicentre Anti-Atheroma Study (MAAS). Investigators (1990). Lancet, 344, 633–8.
MacNeill, B. D., Lowe, H. C., Takano, M., et al. (2003). Intravascular modalities for detection of vulnerable plaque: current status. Arteriosclerosis, Thrombosis and Vascular Biology, 23, 1333–42.CrossRefGoogle ScholarPubMed
MacNeill, B. D., Jang, I. K., Bouma, B. E., et al. (2004). Focal and multi-focal plaque macrophage distributions in patients with acute and stable presentations of coronary artery disease. Journal of American College of Cardiology, 44, 972–9.CrossRefGoogle ScholarPubMed
Matsuzaki, M., Hiramori, K., Imaizumi, T., et al. (2002). Intravascular ultrasound evaluation of coronary plaque regression by low density lipoprotein-apheresis in familial hypercholesterolemia: the Low Density Lipoprotein-Apheresis Coronary Morphology and Reserve Trial (LACMART). Journal of the American College of Cardiology, 40, 220–7.CrossRefGoogle Scholar
Mintz, G. S., Kent, K. M., Pichard, A. D., et al. (1997). Intravascular ultrasound insights into mechanisms of stenosis formation and restenosis. Cardiology Clinics, 15, 17–29.CrossRefGoogle ScholarPubMed
Mintz, G. S., Nissen, S. E., Anderson, W. D., et al. (2001). American College of Cardiology Clinical Expert Consensus Document on Standards for Acquisition, Measurement and Reporting of Intravascular Ultrasound Studies (IVUltrasound). A report of the American College of Cardiology Task Force on Clinical Expert Consensus Documents. Journal of the American College of Cardiology, 37, 1478–92.CrossRefGoogle Scholar
Mintz, G. S., Painter, J. A., Pichard, A. D., et al. (1995). Atherosclerosis in angiographically “normal” coronary artery reference segments: an intravascular ultrasound study with clinical correlations. Journal of the American College of Cardiology, 25, 1479–85.CrossRefGoogle ScholarPubMed
Morino, Y., Bonneau, H. N. and Fitzgerald, P. J. (2001). Vascular brachytherapy: what have we learned from intravascular ultrasound?Journal of Invasive Cardiology, 13, 409–16.Google ScholarPubMed
Naghavi, M., Libby, P., Falk, E., et al. (2003). From vulnerable plaque to vulnerable patient: a call for new definitions and risk assessment strategies: Part I. Circulation, 108, 1664–72.CrossRefGoogle Scholar
Nair, A., Kuban, B. D., Tuzcu, E. M., et al. (2002). Coronary plaque classification with intravascular ultrasound radiofrequency data analysis. Circulation, 106, 2200–6.CrossRefGoogle ScholarPubMed
Nissen, S. E., Tuzcu, E. M., Libby, P., et al. (2004). Effect of antihypertensive agents on cardiovascular events in patients with coronary disease and normal blood pressure: the CAMELOT study: a randomized controlled trial. Journal of the American Medical Association, 292, 2217–25.CrossRefGoogle ScholarPubMed
Nissen, S. E., Tuzcu, E. M., Schoenhagen, P., et al. (2004). Effect of intensive compared with moderate lipid-lowering therapy on progression of coronary atherosclerosis: a randomized controlled trial. Journal of the American Medical Association, 291, 1071–80.CrossRefGoogle ScholarPubMed
Nissen, S. E., Tuzcu, E. M., Schoenhagen, P., et al. (2005). Statin therapy, LDL cholesterol, C-reactive protein, and coronary artery disease. New England Journal of Medicine, 352, 29–38.CrossRefGoogle ScholarPubMed
Nissen, S. E., Tsunoda, T., Tuzcu, E. M., et al. (2003). Effect of recombinant ApoA-I Milano on coronary atherosclerosis in patients with acute coronary syndromes: a randomized controlled trial. Journal of the American Medical Association, 290, 2292–300.CrossRefGoogle ScholarPubMed
Nissen, S. E. and Yock, P. (2001). Intravascular ultrasound: novel pathophysiological insights and current clinical applications. Circulation, 103, 604–16.CrossRefGoogle ScholarPubMed
Okazaki, S., Yokoyama, T., Miyauchi, K., et al. (2004). Early statin treatment in patients with acute coronary syndrome: demonstration of the beneficial effect on atherosclerotic lesions by serial volumetric intravascular ultrasound analysis during half a year after coronary event: the ESTABLISH Study. Circulation, 110, 1061–8.CrossRefGoogle ScholarPubMed
Pasterkamp, G., Wensing, P. J., Post, M. J., et al. (1995). Paradoxical arterial wall shrinkage may contribute to luminal narrowing of human atherosclerotic femoral arteries. Circulation, 91, 1444–9.CrossRefGoogle ScholarPubMed
PDAY Research Group (1990). Relationship of atherosclerosis in young men to serum lipoprotein cholesterol concentrations and smoking. A preliminary report from the Pathobiological Determinants of Atherosclerosis in Youth (PDAY) Research Group. Journal of the American Medical Association, 264, 3018–24.CrossRef
Pinney, S. P. and Mancini, D. (2004). Cardiac allograft vasculopathy: advances in understanding its pathophysiology, prevention, and treatment. Current Opinion in Cardiology, 19, 170–6.CrossRefGoogle ScholarPubMed
Pitt, B., Mancini, G. B., Ellis, S. G., et al. (1995). Pravastatin limitation of atherosclerosis in the coronary arteries (PLAC I): reduction in atherosclerosis progression and clinical events. PLAC I investigation. Journal of the American College of Cardiology, 26, 1133–9.CrossRefGoogle ScholarPubMed
Plump, A. S., Scott, C. J. and Breslow, J. L. (1994). Human apolipoprotein A-I gene expression increases high density lipoprotein and suppresses atherosclerosis in the apolipoprotein E-deficient mouse. Proceedings of the National Academy of Science (UltrasoundA), 91, 9607–11.CrossRefGoogle ScholarPubMed
Ridker, P. M., Cannon, C. P., Morrow, D., et al. (2005). C-reactive protein levels and outcomes after statin therapy. New England Journal of Medicine, 352, 20–8.CrossRefGoogle ScholarPubMed
Ridker, P. M., Rifai, N., Rose, L., et al. (2002). Comparison of C-reactive protein and low-density lipoprotein cholesterol levels in the prediction of first cardiovascular events. New England Journal of Medicine, 347, 1557–65.CrossRefGoogle ScholarPubMed
Rioufol, G., Finet, G., Ginon, I., et al. (2002). Multiple atherosclerotic plaque rupture in acute coronary syndrome: a three-vessel intravascular ultrasound study. Circulation, 106, 804–8.CrossRefGoogle ScholarPubMed
Rong, J. X., Li, J., Reis, E. D., et al. (2001). Elevating high-density lipoprotein cholesterol in apolipoprotein E-deficient mice remodels advanced atherosclerotic lesions by decreasing macrophage and increasing smooth muscle cell content. Circulation, 104, 2447–52.CrossRefGoogle ScholarPubMed
Ross, R. (1999). Atherosclerosis – an inflammatory disease. New England Journal of Medicine, 340, 115–26.CrossRefGoogle ScholarPubMed
Rudd, J. H., Warburton, E. A., Fryer, T. D., et al. (2002). Imaging atherosclerotic plaque inflammation with 18F-fluorodeoxyglucose positron emission tomography. Circulation, 105, 2708–11.CrossRefGoogle ScholarPubMed
Saam, T., Ferguson, M. S., Yarnykh, V. L., et al. (2005). Quantitative evaluation of carotid plaque composition by in vivo Magnetic resonance imaging. Arteriosclerosis, Thrombosis and Vascular Biology, 25, 234–9.Google Scholar
Sacks, F. M., Pfeffer, M. A., Moye, L. A., et al. (1996). The effect of pravastatin on coronary events after myocardial infarction in patients with average cholesterol levels. Cholesterol and Recurrent Events Trial investigators. New England Journal of Medicine, 335, 1001–9.CrossRefGoogle ScholarPubMed
Schaar, J. A., Korte, C. L., Mastik, F., et al. (2003). Characterizing vulnerable plaque features with intravascular elastography. Circulation, 108, 2636–41.CrossRefGoogle ScholarPubMed
Schoepf, U. J., Becker, C. R., Ohnesorge, B. M., et al. (2004). Computerized tomography of coronary artery disease. Radiology, 232, 18–37.CrossRefGoogle ScholarPubMed
Schoenhagen, P., Halliburton, S. S., Stillman, A. E., et al. (2004). Noninvasive imaging of coronary arteries: current and future role of multi-detector row Computerized tomography. Radiology, 232, 7–17.CrossRefGoogle Scholar
Schoenhagen, P., Stone, G. W., Nissen, S. E., et al. (2003). Coronary plaque morphology and frequency of ulceration distant from culprit lesions in patients with unstable and stable presentation. Arteriosclerosis, Thrombosis and Vascular Biology, 23, 1895–900.CrossRefGoogle ScholarPubMed
Schoenhagen, P., Ziada, K. M., Kapadia, S. R., et al. (2000). Extent and direction of arterial remodeling in stable versus unstable coronary syndromes: an intravascular ultrasound study. Circulation, 101, 598–603.CrossRefGoogle Scholar
Schwartz, G. G., Olsson, A. G., Ezekowitz, M. D., et al. (2001). Effects of atorvastatin on early recurrent ischemic events in acute coronary syndromes: the MIRACL study: a randomized controlled trial. Journal of the American Medical Association, 285, 1711–18.CrossRefGoogle ScholarPubMed
Serruys, P. W., Degertekin, M., Tanabe, K., et al. (2004). Vascular responses at proximal and distal edges of paclitaxel-eluting stents: serial intravascular ultrasound analysis from the TAXUltrasound II trial. Circulation, 109, 627–33.CrossRefGoogle ScholarPubMed
Shah, P. K., Nilsson, J., Kaul, S., et al. (1998). Effects of recombinant apolipoprotein A-I(Milano) on aortic atherosclerosis in apolipoprotein E-deficient mice. Circulation, 97, 780–5.CrossRefGoogle ScholarPubMed
Shah, P. K., Yano, J., Reyes, O., et al. (2001). High-dose recombinant apolipoprotein A-IMilano mobilizes tissue cholesterol and rapidly reduces plaque lipid and macrophage content in apolipoprotein E-deficient mice. Circulation, 103, 3047–50.CrossRefGoogle Scholar
Shepherd, J., Cobbe, S. M., Ford, I., et al. (1995). Prevention of coronary heart disease with pravastatin in men with hypercholesterolemia. West of Scotland Coronary Prevention Study Group. New England Journal of Medicine, 333, 1301–7.CrossRefGoogle ScholarPubMed
Stenestrand, U. and Wallentin, L. (2001). Early statin treatment following acute myocardial infarction and 1-year survival. Journal of the American Medical Association, 285, 430–6.CrossRefGoogle ScholarPubMed
Tardif, J. C., Cote, G., Lesperance, J., et al. (2001). Impact of residual plaque burden after balloon angioplasty in the MultiVitamins and Probucol (MVP) trial. Canadian Journal of Cardiology, 17, 49–55.Google ScholarPubMed
Tardif, J. C., Gregoire, J., Schwartz, L., et al. (2003). Effects of AGI-1067 and probucol after percutaneous coronary interventions. Circulation, 107, 552–8.CrossRefGoogle ScholarPubMed
Taylor, A. J., Sullenberger, L. E., Lee, H. J., et al. (2004). Arterial Biology for the Investigation of the Treatment Effects of Reducing Cholesterol (ARBITER) 2: a double-blind, placebo-controlled study of extended-release niacin on atherosclerosis progression in secondary prevention patients treated with statins. Circulation, 110, 3512–17.CrossRefGoogle ScholarPubMed
Tearney, G. J., Yabushita, H., Houser, S. L., et al. (2003). Quantification of macrophage content in atherosclerotic plaques by optical coherence tomography. Circulation, 107, 113–19.CrossRefGoogle ScholarPubMed
Topol, E. J. and Nissen, S. E. (1995). Our preoccupation with coronary luminology. The dissociation between clinical and angiographic findings in ischemic heart disease. Circulation, 92, 2333–42.CrossRefGoogle ScholarPubMed
Tuzcu, E. M., Franco, A. C., Goormastic, M., et al. (1996). Dichotomous pattern of coronary atherosclerosis 1 to 9 years after transplantation: insights from systematic intravascular ultrasound imaging. Journal of the American College of Cardiology, 27, 839–46.CrossRefGoogle ScholarPubMed
Tuzcu, E. M., Kapadia, S. R., Sachar, R., et al. (2005). Intravascular ultrasound evidence of angiographically silent progression in coronary atherosclerosis predicts long-term morbidity and mortality after cardiac transplantation. Journal of the American College of Cardiology, 45, 1538–42.CrossRefGoogle ScholarPubMed
Tuzcu, E. M., Kapadia, S. R., Tutar, E., et al. (2001). High prevalence of coronary atherosclerosis in asymptomatic teenagers and young adults: evidence from intravascular ultrasound. Circulation, 103, 2705–10.CrossRefGoogle Scholar
Urbina, E. M., Srinivasan, S. R., Tang, R., et al. (2002). Impact of multiple coronary risk factors on the intima-media thickness of different segments of carotid artery in healthy young adults (The Bogalusa Heart Study). American Journal of Cardiology, 90, 953–8.CrossRefGoogle Scholar
Verheye, S., Meyer, G. R., Langenhove, G., et al. (2002). In vivo temperature heterogeneity of atherosclerotic plaques is determined by plaque composition. Circulation, 105, 1596–601.CrossRefGoogle ScholarPubMed
Yeung, A. C., Davis, S. F., Hauptman, P. J., et al. (1995). Incidence and progression of transplant coronary artery disease over 1 year: results of a multicenter trial with use of intravascular ultrasound. Multicenter Intravascular Ultrasound Transplant Study Group. Journal of Heart and Lung Transplantation, 14, S215–220.Google ScholarPubMed

Save book to Kindle

To save this book to your Kindle, first ensure [email protected] is added to your Approved Personal Document E-mail List under your Personal Document Settings on the Manage Your Content and Devices page of your Amazon account. Then enter the ‘name’ part of your Kindle email address below. Find out more about saving to your Kindle.

Note you can select to save to either the @free.kindle.com or @kindle.com variations. ‘@free.kindle.com’ emails are free but can only be saved to your device when it is connected to wi-fi. ‘@kindle.com’ emails can be delivered even when you are not connected to wi-fi, but note that service fees apply.

Find out more about the Kindle Personal Document Service.

Available formats
×

Save book to Dropbox

To save content items to your account, please confirm that you agree to abide by our usage policies. If this is the first time you use this feature, you will be asked to authorise Cambridge Core to connect with your account. Find out more about saving content to Dropbox.

Available formats
×

Save book to Google Drive

To save content items to your account, please confirm that you agree to abide by our usage policies. If this is the first time you use this feature, you will be asked to authorise Cambridge Core to connect with your account. Find out more about saving content to Google Drive.

Available formats
×